Peptide News Digest

#Azd9550

2 stories

Research · View digest

AstraZeneca AZD6234 Amylin Peptide Agonist Phase 2 Data Queued for EASD 2026 in Milan September 28 to October 2

AstraZeneca's AZD6234 (a long-acting selective amylin receptor peptide agonist, weekly subcutaneous, currently in Phase 2 for obesity and type 2 diabetes) is queued for Phase 2 data presentations at the European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 to October 2, 2026. Trials on deck: APRICUS (obesity monotherapy) primary data 'imminent' per management; ARAY (NCT06851858, AZD6234 in obesity and type 2 diabetes on stable GLP-1 background); and the ASCEND Phase 2b (NCT06862791, 377 patients) that tests AZD6234 monotherapy, AZD9550 (AZ's GLP-1/glucagon dual agonist) monotherapy, and the combination against placebo over 36 weeks. Preliminary characterization suggests body-fat-selective weight loss and a generally tolerable profile. The readouts will provide a direct comparator against Novo Nordisk's CagriSema (semaglutide plus cagrilintide) and Metsera's MET-233i (monthly amylin) and set the near-term valuation frame for AZ's metabolic disease positioning after the $1.2 billion CSPC obesity licensing announced in January.

Clinical Trials · View digest

AstraZeneca ASCEND Triple-Mechanism Phase 2b Active: AZD9550 GLP-1/Glucagon Dual + AZD6234 Selective Amylin via CSPC Pharmaceuticals Collaboration

AstraZeneca's ASCEND program is active in Phase 2b, combining AZD9550 (GLP-1 + glucagon dual agonist) with AZD6234 (selective amylin analog) in a two-molecule triple-mechanism strategy aimed at fat-selective weight loss and organ protection. Individual assets are also in Phase 2. The combination reflects the February 2026 $1.2 billion CSPC Pharmaceuticals collaboration that brought both molecules into AstraZeneca's portfolio, alongside elecoglipron (AZD5004 / ECC5004), the small-molecule oral GLP-1 that posted 5.8% weight loss over four weeks in Phase 1b in China. AstraZeneca enters the next-gen obesity race later than Lilly, Novo, Roche, and Boehringer, but the triple-mechanism positioning targets the safety + organ-protection lane that competitors leave open.